These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8845477)
1. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers. Didier A; Wenger J; Loor F Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477 [TBL] [Abstract][Full Text] [Related]
2. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Jiang XR; Kelsey SM; Wu YL; Newland AC Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760 [TBL] [Abstract][Full Text] [Related]
3. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents. Jachez B; Loor F Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300 [TBL] [Abstract][Full Text] [Related]
4. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Lopes EC; Scolnik M; Alvarez E; Hajos SE Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565 [TBL] [Abstract][Full Text] [Related]
5. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Tiberghien F; Loor F Anticancer Drugs; 1996 Jul; 7(5):568-78. PubMed ID: 8862725 [TBL] [Abstract][Full Text] [Related]
6. Detection of P-glycoprotein expression by tumoral cells with NBDL-CsA, a fluorescent derivative of cyclosporin A. Didier A; Tiberghien F; Wenger R; Loor F Anticancer Drugs; 1996 May; 7(3):257-65. PubMed ID: 8791998 [TBL] [Abstract][Full Text] [Related]
7. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Didier A; Loor F Anticancer Drugs; 1996 Sep; 7(7):745-51. PubMed ID: 8949985 [TBL] [Abstract][Full Text] [Related]
8. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. Loor F; Tiberghien F; Wenandy T; Didier A; Traber R J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387 [TBL] [Abstract][Full Text] [Related]
9. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128 [TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140 [TBL] [Abstract][Full Text] [Related]
11. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Boesch D; Loor F Anticancer Drugs; 1994 Apr; 5(2):229-38. PubMed ID: 7914109 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Ross DD; Wooten PJ; Sridhara R; Ordóñez JV; Lee EJ; Schiffer CA Blood; 1993 Aug; 82(4):1288-99. PubMed ID: 8102561 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293 [TBL] [Abstract][Full Text] [Related]
14. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Lehne G; De Angelis P; den Boer M; Rugstad HE Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882 [TBL] [Abstract][Full Text] [Related]
15. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Leontieva OV; Preobrazhenskaya MN; Bernacki RJ Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193 [TBL] [Abstract][Full Text] [Related]
16. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539 [TBL] [Abstract][Full Text] [Related]
18. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia. Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923 [TBL] [Abstract][Full Text] [Related]
19. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia. Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein. Lehne G; Rugstad HE Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]